The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Polar sold around 320,000 yesterday. If you look at the trades over an hour or so around midday they look as if they were all sold at a profit. The stock market is not for the blind. The stock had to be coming from somewhere and one of the three institutional holders had to be the culprit. There can't be many if any quoted companies as illiquid as Redx
The seller has a lot to dispose of! Polar paid 26p for their last tranche. Most of the buyers early yesterday took stock off them. MM's had a field day. Most of the theories offered here were way off the mark. These are a long-term hold. Too little stock available unless Polar or other large holders want to sell. Look at the history of when they reached 122p. Purely lack of stock.
Shareholder Number of ordinary Percentage of issued
shares share capital
Funds managed by Redmile
Group LLC 276,890,319 71.18
------------------- ---------------------
Sofinnova Crossover
I SLP 51,948,307 13.35
------------------- ---------------------
Polar Capital LLP 24,321,504 6.25
------------------- ---------------------
Invus Public Equities
L.P. 15,203,815 3.91
------------------- ---------------------
Total 95.31%
Total Shares Outstanding 388,985,916
Therefore free float 4.69% is held by directors and shareholders .
This is FACT
Zura Biotech launched via a SPAC on Nasdaq yesterday with a placing price of $7. The closing price was $32 after a huge turnover. They are currently just under $30.
I won't go into much detail, but they are so similar in many respects to RedX. However, the valuation is massively different in REDx's favour. I seriously suggest you check for yourselves. All the usual websites are worth looking at.
Even their labs etc are only a couple of miles away from Redx's in Cheshire.
My conclusion is that REDx shares are a bargain. Please be free to give your opinion as it seems too good an opportunity to me.
Have always expected Nasdaq to be a likely outcome since the appointment of CFO, Peter Collum, based in the states. Never saw why they couldn't find a CFO of equal merit in the UK.
The next fundraising will be interesting, particularly if a new fund decides to participate.
Happy Christmas everyone.
Shearclass,
Do you have any comments on the annual update and video cast yesterday? Also, the new options issued and the 10% drop in the SP since.
Seems to me that the share price drop is of little relevance in the short term as biotechs should really be considered with a 5/10 year view on the basis that they 'come up trumps' eventually. With that in mind and having been invested for over two years, I feel as sure as ever that this is a superbly well-run operation with a collection of very talented individuals, in particularly Lisa Anson. I am sure patience will see many lives being prolonged and shareholders being handsomely rewarded if the current progress is continued.
Hoping for a possible update on progress. Don't expect the figures to be anything of a surprise, either negative or positive.
All the news on research has continually been positive, future finance has always been agreed upon well in advance.
However, patience is required for any meaningful financial benefit to minority shareholders.
If the research continues positively it won't just be shareholders who benefit. Good luck all.
The SP needs some good updates on progress at the moment. The company has been quiet of late. Maybe we will hear something next week with the Finals. There seems a lot going on under the radar so I have no concerns but the SP has stagnated around 60p for nearly 3 years, principally due to annual dilutions. It would be good to at least have the option to participate in the fundings. Another must be due in the next six months.
Just an aside, do we have many private investors still holding either of the Craven entities shares? Would be interesting to see the share register to just who is still holding. It could reveal a lot! But there again it is probably completely out of date and would be misleading as everything to do with CRV has always been. It would make a very interesting book but everyone who read it would never believe it was all actually fact. John Le Carre couldn’t have made it up.
I posted the following in early 2020. Has anyone any answers/comments to the points I raised? See post copies below
We have all really been sold down the river over the last 15 years. It’s incredible that companies ( in this case one person) can get away with what charitably could be described as bad management, but in truth must be fraudulent trading. The regulators are toothless and allow this sort of thing to happen. No Aim directors ever seem to be taken to task when they run companies into the ground whilst lining there own pockets. There are too many companies where this has happened and Aim rules need totally rewriting to protect shareholders and not the principals.
Has anybody any idea of the mechanics of the trading arrangements for CIH? If there are buyers and/or sellers how is that fact imparted to shareholders or other potential investors? I seem to remember trading is intended to be available on a regular basis. So far I have no idea of the true value of the assets in CIH other than by a very unsophisticated way using the back of a fag packet or Abacus. It would be very useful to believe that the procedure will be done in an open and transparent way. Past experience over the last 12 years suggests it won't be. I am led to assume that everything will be handled purely in the director(s) and large shareholder's best interests. I could be a buyer, I could be a seller but at what price I haven't a clue. Any information on these matters would be very helpful. I really feel once again I have been taken for a mug! Come on Mr Pajak, try looking after the small band of shareholders who against all sound judgement have stood by you all these years. We really could do with some reward for our support! Go on surprise us.
Possibly due to the sale of 500000 at the end of last week. These probably were the 500000 shares from the exercise of options by an ex-director earlier in the week.
Any buying or selling, even in such small quantities as today, produces large movements due to lack of available free stock. All is looking very positive for Redx, with a good flow of news on the progress of the research. Redx has a number of lines of research all showing great prospects. They also have a lot of interest and support from major large pharmas. They are also assembling a highly qualified team of top scientists in their fields.
There is always the possibility of a Nasdaq quote. ( purely my supposition due to Redx recently appointing a Finance Director domicile in The USA.)
Medium to longer-term Redx could develop into a major player in medical research. So far it is very much under the radar of investors.
Possibly the sale to safe hands of the 500,000 exercised options at the end of last week. Must be no stock about now that the short-termers sold out in the retracement to 75p following the rapid rise to 129. Taken very few buys this am to get a rise of 10%. Redex seems to be on the cusp of some really exciting and transformational news over the next 12 months and that news could come at any time.
The SP suggests another issue of options is on the cards. Price-performance over the last 2/3 weeks has been very hard to comprehend. The lack of free shares makes for volatility in certain circumstances but retracing all the gains seems very strange. All news has been positive and there is a presentation next week which one would expect to have some more optimism on the progress on the various strands of research. With the benefit of hindsight, I should have sold out at 120ish and repurchased today!! However when in for the long term it hardly matters...but it is very annoying at the same time!